

Euregionales comprehensive Cancer Center Aachen (ECCA)

> New Drugs in Hematology Bologna, May 9th to May 11th, 2016

## Bosutinib: innovation to CML treatment or *"just another 2<sup>nd</sup> generation TKI*"?

Prof. Dr. med. Tim H Brümmendorf Klinik für Hämatologie und Onkologie Universitätsklinikum Aachen



#### **Challenges in Treatment of CML in 2016**




<u>Background</u>: Most patients with newly diagnosed CML are assumed to have a normal life-expectancy.

The <u>challenges in CML treatment</u> are focussed on

- 1. Offer the perspective of a **treatment-free remission** (cure ?) to as many as possible patients
- 2. Prevention of and (in case it happens) improved treatment of
  - disease progression to AP/BC and
  - development of resistance to TKI
- 3. Improvement of **tolerability** and **adherence** to TKI
- **4. Eradiaction** of **leukemic stem cells** as a continued source of relapse/disease progression



#### Bosutinib: A Dual Inhibitor of Src and Abl Kinases



Puttini M, et al. *Cancer Res.* 2006;66(23):11314-11322. Courtesy of Scapozza L and Shaheen A, University of Geneva, Switzerland.



Src enzyme (ELISA)  $IC_{50} = 1.2 \text{ nM}$ Src enzyme (Lance)  $IC_{50} = 3.8 \text{ nM}$ Abl enzyme  $IC_{50} = 1.4 \text{ nM}$ 


K562 cell  $IC_{50} = 20 \text{ nM}$ KU812 cell  $IC_{50} = 4.3 \text{ nM}$ 

<u>Once daily</u> oral application ! independent of food !

> Boschelli DH, et al. *J Med Chem.* 2005;48(11):3891-3902. Golas JM, et al. *Cancer Res.* 2003;63(2):375-381. Golas JM, et al. *Cancer Res.* 2005;65(12):5358-5364.

## **Evolution of targeted therapy of CML:** A simplified view






reviewed in: Balabanov, Braig and Brümmendorf Drug Discovery Today 2014; 11:89-99





#### Molecular Targets of 1st and 2nd generation TKIs



Balabanov, Braig and Brümmendorf Drug Discov Today Technol. (2014) 11:89-99



#### Resistance spectrum of TKIs in CML



Parental WT M244V L248R L248V G250E Q252H Y253F Y253H	Imatinib 10,8 1 0,9 14,6 3,5 6,9	Bosutinib 38,3 1 0,9 22,9 3,5	Dasatinib 568,3 1 2,0 12,5	Nilotinib 38,4 1 1,2	Ponatinib 570,0 1 3,2	DCC-2036 13,1 1
WT M244V L248R L248V G250E Q252H Y253F	1 0,9 14,6 3,5 6,9	1 0,9 22,9	1 2,0	1 1,2	1	1
M244V L248R L248V G250E Q252H Y253F	0,9 14,6 3,5 6,9	0,9 22,9	2,0	1,2		1
L248R L248V G250E Q252H Y253F	14,6 3,5 6,9	22,9	2,0 12,5	1,2	3.0	
L248V G250E Q252H Y253F	14,6 3,5 6,9	22,9	12,5		J,C	0,8
G250E Q252H Y253F	<mark>3,5</mark> 6,9			30,2	6,2	0,4
Q252H Y253F	6,9		5,1	2,8	3,4	1,3
Y253F		4,3	4,4	4,6	6,0	3,0
Y253F	1,4	0,8	3,1	2,6	6,1	2,1
	3,6	1,0	1,6	3,2	3,7	2,3
12300	8,7	0,6	2,6	36,8	2,6	2,7
E255K	6,0	9,5	5,6	6,7	8,4	3,5
						2,1
						4,5
						6,5
						1,0
						0,3
						0,0
						0,7
						0,6
						1,1
		235				21,0
						6,6
						1,0
						2,2
						0,7
						0,7
						· · · · · · · · · · · · · · · · · · ·
						0,9
				2,4		1,5
						0,7
				1,9		0,5
L248R + F359I	11,7	39,3	13,7	96,2	17,7	1,0
<2						
2.1-4						
	E255V D276G E279K E292L V299L T315A T315I T315V F317L F317R F317V M343T M351T F359I F359V L384M H396P H396R F486S L248R + F359I	E255V       17,0         D276G       2,2         E279K       3,6         E292L       0,7         V299L       1,5         T315A       1,7         T315J       17,5         T315V       12,2         F317L       2,6         F317R       2,3         F317V       0,4         M343T       1,2         M351T       1,8         F359I       6,0         F359V       2,9         L384M       1,3         H396P       2,4         H396R       3,9         F486S       8,1         L248R + F359I       11,7	E255V $17,0$ $5,5$ D276G $2,2$ $0,6$ E279K $3,6$ $1,0$ E292L $0,7$ $1,1$ V299L $1,5$ $26,1$ T315A $1,7$ $6,0$ T315I $17,5$ $45,4$ T315V $12,2$ $29,3$ F317L $2,6$ $2,4$ F317R $2,3$ $33,5$ F317V $0,4$ $11,5$ M343T $1,2$ $1,1$ M351T $1,8$ $0,7$ F359I $6,0$ $2,9$ F359V $2,9$ $0,9$ L384M $1,3$ $0,5$ H396P $2,4$ $0,4$ H396R $3,9$ $0,8$ F486S $8,1$ $2,3$ L248R + F359I $11,7$ $39,3$	E255V17,05,53,4D276G2,20,61,4E279K3,61,01,6E292L0,71,11,3V299L1,526,18,7T315A1,76,058,9T315I17,545,475,0T315V12,229,3738,8F317L2,62,44,5F317R2,333,5114,8F317V0,411,521,3M343T1,21,10,9M351T1,80,70,9F359I6,02,93,0F359V2,90,91,5L384M1,30,52,2H396P2,40,41,1H396R3,90,81,6F486S8,12,33,0L248R + F359I11,739,313,7	E255V17,05,53,410,3D276G2,20,61,42,0E279K3,61,01,62,0E292L0,71,11,31,8V299L1,526,18,71,3T315A1,76,058,92,7T315I17,545,475,039,4T315V12,229,3738,857,0F317L2,62,44,52,2F317R2,333,5114,82,3F317V0,411,521,30,5M343T1,21,10,90,8M351T1,80,70,90,4F359I6,02,93,016,3F359V2,90,91,55,2L384M1,30,52,22,3H396P2,40,41,12,4H396R3,90,81,63,1F486S8,12,33,019,9L248R + F359I11,739,313,796,2	E255V17,05,53,410,312,9D276G2,20,61,42,02,1E279K3,61,01,62,03,0E292L0,71,11,31,82,0V299L1,526,18,71,30,6T315A1,76,088,92,70,4T315I17,545,475,039,43,0T315V12,229,3738,857,02,1F317L2,62,44,52,20,7F317R2,333,5114,82,34,9F317V0,411,521,30,52,3M343T1,21,10,90,80,9M351T1,80,70,90,41,2F359I6,02,93,016,32,9F359V2,90,91,55,24,4L384M1,30,52,22,32,2H396P2,40,41,12,41,4H396R3,90,81,63,15,9F486S8,12,33,013,796,217,7






Euregionales comprehensive Cancer Center Aachen (ECCA)

## Study 200: Bosutinib in Previously Treated CML Patients



#### Study 200: Patient Cohorts (n=570) in 2<sup>nd</sup>+ line





1. Cortes JE, et al. Blood. 2011;118:4567-4576; 2. Khoury HJ, et al. Blood. 2012;119:3403-3412.


#### Second-Line CP Cohort (Bosutinib post IM)

Bosutinib- treated patients	Response						
	MCyR CCyR MMR					MR	
	n	%	n	%	n	%	
Total population	156/ 262	60	130/ 262	50	69/200	35	
IM-R	107/ 182	59	88/182	48	45/132	34	
IM-I	49/80	61	42/80	53	24/68	35	

 Most MCyR responses were newly attained (54%) rather than maintained from baseline (6%), min. F/U 60 months

#### **Duration of MCyR (Among Responders)**

(B) Duration of MCyR




Brümmendorf et al. Br. J. Hematol. 2016;172:97-110

## Bosutinib – Response Rates and Duration of Response (3<sup>rd+</sup> line); min F/U 48 months

Bosutinib-treated Patients	Response					
	МС	SyR	CCyR			
	n %		n	%		
Total population	45/112	40	36/112	32		
IM + DAS-R	14/39	36	8/39	21		
IM + DAS-I	19/42	45	18/42	43		
IM + NIL-R	10/26	38	8/26	31		
IM + DAS +/- NIL	2/5	40	2/5	40		

Most MCyR responses were newly attained (33%) rather than maintained from baseline (7%)

#### **Duration of MCyR (Among Responders)**



Cohort	n	K-M Estimate of Maintaining MCyR at 4 Y, % (95% CI)
Total	45	69 (52–81)
IM + D-R	14	43 (16–68)
IM + D-I	19	87 (57–97)
IM + N-R	10	78 (37–94)
IM + N±D	2	not reported

Gambacorti-Passerini, et al. Blood. 2014;124(21): Abstract 4559 (ASH 2014).




Euregionales comprehensive Cancer Center Aachen (ECCA)

## Study 3000: Bosutinib in first line treatment of CML CP Patients



# Bosutinib Efficacy and Safely in Newly Diagnosed CML (BELA): Study Design



- Primary endpoint: complete cytogenetic response (CCyR) rate at 12 mo
- Secondary endpoints:
  - Major molecular response (MMR) rate at 12 mo
  - Time to CCyR and MMR
  - Time to and rate of transformation to accelerated phase (AP) or blast phase (BP) CML
  - Safety and tolerability

#### Cumulative MMR: First line TKI studies in CML



Comparison of independent studies with differences in study design

MMR	12 Months	24 Months	36 Months
CML IV IM 400 / IM 800 / IM + IFN	<mark>31%</mark> / 55% / 35%	<mark>63%</mark> / 76% / 63%	<mark>79%</mark> / 82% / 71%
ENESTnd IM 400 / NIL 600 / NIL 800	27% / <mark>51%*</mark> / 55%*	44% / <mark>67%*</mark> / 71%*	53% / 70%*/ 73%*
DASISION IM 400 / DAS 100	23% <b>/ 46%*</b>	46% <b>/ 64%*</b>	55% <b>/ 68%</b> *
BELA IM 400 / BOS 500	32% <b>/ 47%</b> *	52% <b>/ 67%</b> *	52% / 61%* (30 Monate)

Hehlmann et al., 2011, J Clin Oncol, 29, 1634-42 Larson et al., 2012, Leukemia Saglio et al., 2010, N Engl J Med, 362, 2251-9 Hochhaus et al., Abstract 6504, ASCO 2012 Gambacorti et al. ASCO 2011; Brümmendorf et al., ASH 2012 \* p=<0,05



#### Disease Progression: First line TKIs in CML




	Progression AP/BC	Progression (CML related)
CML IV (2 years) IM 400 / IM 800 / IM + IFN		<mark>4%</mark> / 6% / 5%
ENESTnd (3 years) IM 400 / NIL 600 / NIL 800	6,7% / 2,1%* / 3,2%*	
DASISION (3 years) (ITT) IM 400 / DAS 100	6,2% / 4,2%	
BELA (2 years) IM 400 / BOS 500	5% <b>/ 2%</b>	

Hehlmann et al., 2011, J Clin Oncol, 29, 1634-42 Saglio et al., ASH 2011 Hochhaus et al., Abstract 6504, ASCO 2012 Gambacorti-Passerini et al., ASCO 2011, Brümmendorf et al. ASH 2012 \* p=<0,01



### BELA Study (3000): CCyR and MCyR




Primary study endpoint

Jorge E. Cortes et al. J. Clin. Oncol. 2012;30:3486-3492








Brümmendorf et al. Br. J. Hematol. 2015;168:69-81







- Key eligibility criteria: Chronic Phase CP CML ≤6 months prior, no prior therapy (other than hydroxyurea or anagrelide)
- Primary endpoint: Major molecular response at 12 months (48 weeks)
- Key secondary endpoints
  - MMR by 18 months, duration of MMR, CCyR by 12 months, duration of CCyR, event-free survival (EFS), and overall survival (OS)

#### Lead investigators:

Jorge Cortes, Houston (North America) Tim Brümmendorf, Aachen (Europe)

#### **AVILLION**




Euregionales comprehensive Cancer Center Aachen (ECCA)


## Bosutinib: toxicity profile and specificities




#### Study 200: Bosutinib AEs ≥10% Sorted by Grade 3/4 Events (n=570)



#### Study 200: Bosutinib AEs ≥10% Sorted by Grade 3/4 Events (n=570)



#### Study 200: Onset and Duration of Selected AEs



\* Myelosuppression events include anaemia, hemoglobin decreased, neutropenia, neutrophil count decreased, thrombocytopenia, and platelet count decreased. Figure refers to grade 3/4 events (n=231)

Multicenter, open-label single arm phase II study testing tolerability and efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Nilotinib or Dasatinib therapy


"Bosutinib Dose Optimization Study - BODO-Study" (CML-7)

#### Dominik Wolf und Tim Brümmendorf Medizinische Universitäten Bonn und Aachen





#### CML-7 (BODO) Study: Synopse



#### Vascular TEAEs: (Exposure-Adjusted Rate and SOC Incidence)

	Phase 1/2 Study BOS (n=570)		BELA				Total	
			BOS (n=248)			IM (n=251)		Pooled BOS (n=818)
	All Grade	Grade 3/4	All Grade	Grade 3/4	All Grade	Grade 3/4	All Grade	Grade 3/4
Exposure-adjusted vascular TEAE rate <sup>*</sup>	0.08	0.03	0.04	0.01	0.03	0.01	-	-
Any vascular TEAEs, %	15	6	12	2	10	2	14	5
Cardiovascular	4	2	2	1	2	<1	4	2
Cerebrovascular	2	1	1	<1	1	<1	2	1
Peripheral vascular	9	3	9	1	6	1	9	2

\*Computed as the number of patients with events/total patient-year where total patient-year=sum of time to first TEAE for patients with cardiac TEAEs plus time on treatment for patients without cardiac TEAEs TEAEs graded by NCI CTCAE v3.0; coded and classified by MedDRA (v≥15.0)

 Only 1 patient treated with BOS reported PAOD (considered by investigator unrelated to BOS)

PAOD=peripheral arterial occlusive disease; SOC=system organ class.

Cortes, et al. Vascular Toxicity with Bosutinib. ESH-iCMLf; 2014. Abstract 1782.



Figure. Forest Plots of the Outcomes of Interest in Patients With Ph+ Leukemia Treated With New-Generation TKIs vs Imatinib

Vascular occlusive events Α Peto Odds Ratio Favors New-Favors Source (95% CI) Imatinib Generation TKI P Value Weight, % Bosutinib NCT00574873-BELA 2.77 (0.39-19.77) .31 100 .31 Subtotal 2.77 (0.39-19.77) Dasatinib NCT00070499 7.39 (0.15-372.38) .32 7.37 4.46 (0.23-86.51) .32 NCT00103844-START-R 12.88 NCT00320190 0.09(0.00-4.61).23 7.11 .02 NCT00481247-DASISION 4.86 (1.30-18.12) 65.29 NCT00852566-NordCML006 8.09 (0.16-409.34) .30 7.35 Subtotal 3.86 (1.33-11.18) .01 Nilotinib NCT00471497-ENESTnd 3.31 (1.95-5.61) <.001 89.00 NCT00760877-ENESTcmr 4.45 (0.99-20.02) .052 11.00 <.001 Subtotal 3.42 (2.07-5.63) Ponatinib NCT01650805-EPIC 3.47 (1.23-9.78) .02 100 .02 Subtotal 3.47 (1.23-9.78) Overall 3.45 (2.30-5.18) <.001 1 1 1 1 1 1 1 1 0.01 0.1 1.0 10 100 Peto Odds Ratio (95% CI)

Douxfils et al. JAMA Oncol. 2016; Feb 4th





Euregionales comprehensive Cancer Center Aachen (ECCA)

#### Summary

- Bosutinib is a 2<sup>nd</sup> generation TKI with a characteristic molecular profile
- Bosutinib has shown activity against a wide variety of resistanceconfering mutations found in CML patients in 2<sup>nd</sup>+ line
- **BELA trial** using 500 mg Bosutinib first line has failed to reach primary endpoint (CyR rate @12 months), **BFore study** with Bosutinib @400 mg finished recruitment last summer
- side effect profile is *distinct* and partly differs from other 2<sup>nd</sup> generation TKIs

GI toxicities are common, occur typically early under treatment and are often self-limiting (*run-in dosing concepts* currently being investigated)
no evidence exists so far indicating a significantly increased risk of cardiovascular or other *irreversible* toxicities compared to Imatinib

